Law360, New York (January 12, 2007, 12:00 AM ET) -- As the U.S. House of Representatives prepares to consider a bill reforming Medicare Friday, the acting director of the Congressional Budget Office has said that requiring the federal government to negotiate Medicare drug prices would not save money as proponents have long contended.
Acting Director Donald B. Marron wrote a letter Wednesday to Rep. John D. Dingell (D-Mich.), chair of the House Committee of Energy and Commerce, saying that negotiation with the drug companies would have a negligible effect. He argued the government would be unable...
Debate On Proposed Medicare Changes Heats Up
To view the full article, take a free trial now.
